BGPT: Paper Review: Blind docking of pharmaceutically relevant compounds using RosettaLigand

Fuel Your Discoveries

Low confidence. Please provide more context.

Quick Explanation Copied

Blind, private-data evaluation of RosettaLigand docking

On a proprietary GSK “blind” set (8 receptors, 136 ligands), RosettaLigand’s pose recovery is often comparable to leading commercial docking tools, while failures cluster around sampling/search (deep-pocket geometry, insufficient conformational exploration) and scoring (hydrogen-bond directionality, hydrophobic/implicit-solvation issues, limited tautomer/protonation variation).

Long Explanation

Paper Review (Visual): Blind docking of pharmaceutically relevant compounds using RosettaLigand

DOI: 10.1002/PRO.192

Evidence anchor: all quantitative claims below are computed directly from the paper’s Table I and its described protocol/results.

What the authors did (blind protocol, real-world-ish evaluation)

Blindness rationale: public benchmarks may be non-representative and non-blind because binding modes can be known; the paper uses private GSK data to avoid foreknowledge of experimentally determined binding modes.
Dataset: 8 receptors and 136 ligands across 21 ligand classes, with evaluation on RMSD≤2 Å.
Docking setup (as reported): binding-site diameter reduced to 6 Å and 1000 trajectories used (vs 10 Å and 5000 trajectories in earlier work), total runtime ~4 days on 100 processors (~35 processor-hours/compound).
Pose evaluation: either the lowest energy pose (“Best scoring pose”) or the best pose among the 20 lowest-energy unique poses (“Any Pose”), with success defined as ≤2 Å RMSD.

Key quantitative results (computed from Table I)

Table I reports “Any pose” and “Best scoring pose” success rates. Below, we visualize those values directly.

Receptor-by-receptor success table (verbatim from Table I)

Receptor	Any pose within 2 Å RMSD (top 20)	Best scoring pose within 2 Å RMSD (lowest-energy)
Chk1	88% (15/17)	59% (10/17)
FXa	38% (6/16)	31% (5/16)
GyrB	29% (2/7)	29% (2/7)
HCVP	40% (6/15)	7% (1/15)
MRS	12% (4/33)	3% (1/33)
PDF	63% (5/8)	50% (4/8)
PPARδ	43% (23/53)	21% (11/53)

Note: The chart is not a dataset frequency estimate; it simply encodes that the paper dedicates subsections to these issues.

Mechanistic interpretation (what the results imply, cautiously)

1) Search vs scoring is separable in this design

When Any Pose is high but Best scoring is low, the paper’s protocol suggests RosettaLigand can find near-native-like poses but sometimes fails to rank them highest. This is consistent with their stated emphasis that failures arise from both search and scoring, but that search issues are more significant for RosettaLigand in this set.

2) MRS is the standout failure target (sampling limitations are implicated)

MRS shows low success for both Any Pose (12%) and Best scoring (3%). The authors report that multiple issues affected predictions and argue that failures are related to insufficient sampling; they state that greater sampling converted some MRS failures into successes.

3) Hydrogen-bond and solvation model limitations are explicitly highlighted

The authors state that for multiple receptors, best poses may be near-native but miss additional hydrogen bonds, and that this can prevent energy-based discrimination. They also state a clear scoring problem for hydrophobic interactions in PPARD-like ligands, where implicit solvation and hydrophobic scoring may misrank poses.

Skeptical note on inference

Even though the top-20 vs lowest-energy split is informative for disentangling “search” from “scoring,” this interpretation still relies on the paper’s internal RMSD-based proxy for “native-like pose” and on their chosen evaluation window (top 20). In particular, pose recovery and energy ranking do not directly establish thermodynamic accuracy of binding; no experimental affinity correlation is reported in the provided text for this study (it is a docking pose benchmark).

Major limitations / blind spots (what could mislead readers)

Non-public data constrains independent reproducibility. The protocol is blind using private GSK data, and the paper states that the test data are provided by GSK; underlying data are not publicly released in the provided text.
Time budget forced reduced sampling. The docking run used 1000 trajectories instead of earlier 5000 (and a smaller binding-site diameter). That can systematically under-sample difficult cases (consistent with their MRS narrative).
Tautomer/protonation was not exhaustively explored. Due to time constraints, only a single physically reasonable tautomer/protonation state was used, which the paper explicitly says can make accurate energy evaluation impossible.
Conformer-library constraints affect H-bonding and torsional “hopping.” The authors argue that minimization of ligand torsions rarely crosses barriers, limiting access to correct H-bond orientations if not near an input conformer.
Implicit solvation/hydrophobic scoring may be systematically biased. The hydrophobic/solvation subsection argues the implicit model and scoring can make multiple near-isoenergetic poses, leading to incorrect best-scoring outputs.

How to strengthen this line of evidence (what would disprove/upgrade the claims)

Independent blind replication on a different private (or carefully anonymized public) dataset with the same evaluation design, to test whether the performance comparability to commercial tools holds beyond GSK’s specific ligand/receptor selection.
Controlled sampling ablations (keeping scoring constant) to quantify whether the gap between Any Pose and Best scoring narrows with increased sampling budget across targets, especially MRS. The paper itself suggests increased sampling would help for MRS.
Explicit tautomer/protonation ensembles with the same blind evaluation protocol to measure whether energy ranking improves when the correct microscopic states are included (or whether H-bond/hydrophobic issues persist).

Author reviews (open BGPT deep dives)

Jump to bespoke critiques from each full author name found in the provided paper metadata.

Feedback:

Updated: April 17, 2026